Abstract
AbstractRuxolitinib is an orally administered JAK2 inhibitor for the treatment of disease‐related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
